Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...
Sobi to advance Gamifant in interferon-gamma-driven sepsis based on EMBRACE topline data: Stockholm Friday, January 9, 2026, 11:00 Hrs [IST] Sobi, a global biopharma company, anno ...
Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...
A brain parasite infects the very cells meant to stop it. Scientists now know how the body still manages to fight back.
Researchers have identified adaptive traits in cancer cells that help tumors resist immunotherapy drugs after extended targeted treatment, revealing new hurdles to effective cancer treatment. A ...
Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?
Stanford researchers identified a two-step immune process causing rare myocarditis after mRNA COVID-19 vaccines, primarily in ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
Gut microbes may play a key role in training a mother's immune system to adapt to the developing fetus during pregnancy, according to a preclinical ...
New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback